Skip to content
An Initiative of AVAC
Search
Back to Resource Library

Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled analysis from 72 global studies

7 June 2024

This article from Clinical Infectious Diseases reviews 72 prospective studies of daily oral PrEP (TDF/FTC) to evaluate its impact on HIV-1 incidence, drug resistance, adherence, and bone and renal safety in diverse settings.

Topic(s): Research

Product(s): Oral PrEP, TDF/xTC

Format(s): Journal Article

Source(s): Clinical Infectious Diseases

Type: External Link

Visit

Featured Resources

External Link

Interest in Injectable and Oral PrEP for HIV Prevention Among Women and Men Who Inject Drugs

This article from Journal of Addiction Medicine examines interests and concerns around use of oral and injectable PrEP amongst people who inject drugs in the United States.
Document

PrEP Booklet of Frequently Asked Questions (FAQs): A Peer Outreach Worker Tool

This tool was developed to be used by peer outreach workers, peer educators, and other community-based health providers to help provide comprehensive information about pre-exposure prophylaxis (PrEP) to key population peers.
External Link

Determinants of Continuation on HIV Pre-exposure Propylaxis among Female Sex Workers at a Referral Hospital in Uganda: A mixed methods study using COM-B model

This article from BMC Public Health describes the results of a study to evaluate PrEP continuation among female sex workers and explore potential determinants of PrEP adherence within a public referral hospital in urban Uganda.
Document

Oral PrEP Factsheet

This adaptable factsheet can be used by program implementers to raise awareness about oral pre-exposure prophylaxis (PrEP). It highlights tips for using oral PrEP, side effects, and dosing regimens for different groups of people.
Document

PEP Template Guidelines (English)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) post-exposure prophylaxis (PEP) recommendations and guidance. The document includes prompts for national-level consideration during the guideline adaptation process.
Document

Global Acute HIV Infection Algorithm Job Aids for Providers

This tool can assist providers in assessing acute HIV infection (AHI) in clients using oral PrEP, PrEP ring, and CAB PrEP by offering guidance through three steps: HIV testing, recent exposure to HIV assessment, and AHI assessment. Providers are encouraged to use clinical judgement and defer to national guidance as needed.
Document

Daily Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (Spanish)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…
Document

HIV Prevention User Journey Tool

The HIV Prevention Journey Tool was developed to support adolescent girls and young women to explore methods that would align with their lifestyle, needs and personal preferences; and support healthcare providers to provide informed counseling based on client needs. The digital tool, which has been optimized for use on mobile devices, can be accessed here.…
Spreadsheet

2024 Q3 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…
Document

Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (English)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…